scispace - formally typeset
Open AccessPosted ContentDOI

T cell co-stimulatory receptor CD28 is a primary target for PD-1-mediated inhibition

TLDR
It is demonstrated that the coreceptor CD28 is strongly preferred over the TCR as a target for dephosphorylation by PD-1- recruited Shp2 phosphatase, suggesting that costimulatory pathways may play unexpected roles in regulating effector T cell function and therapeutic responses to anti-PD-L1/PD-1.
Abstract
Programmed death-1 (PD-1) is a co-inhibitory receptor that suppresses T cell activation and is an important cancer immunotherapy target. Upon activation by its ligand PD-L1, PD-1 is thought to suppress signaling through the T cell receptor (TCR). Here, by titrating the strength of PD-1 signaling in both biochemical reconstitution systems and in T cells, we demonstrate that the coreceptor CD28 is strongly preferred over the TCR as a target for dephosphorylation by PD-1- recruited Shp2 phosphatase. We also show that PD-1 colocalizes with the costimulatory receptor CD28 in plasma membrane microclusters but partially segregates from the TCR. These results reveal that PD-1 suppresses T cell function primarily by inactivating CD28 signaling, suggesting that costimulatory pathways may play unexpected roles in regulating effector T cell function and therapeutic responses to anti-PD-L1/PD-1.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy.

TL;DR: An overview of the multifaceted positive and negative effects of TH cells, with an emphasis on regulation of different TH cell subtypes by various immune cells, and how a delicate balance of contradictory signals can influence overall success of cancer immunotherapy is presented.
Journal ArticleDOI

Programmed death ligand 1 signals in cancer cells

TL;DR: The recent discovery of cancer cell-intrinsic programmed death ligand 1 (PDL1) signals has broadened understanding of pathologic tumour PDL1 signal consequences that now includes control of tumour growth and survival pathways, stemness, immune effects, DNA damage responses and gene expression regulation as discussed by the authors .
Journal ArticleDOI

Programmed death ligand 1 signals in cancer cells

TL;DR: The recent discovery of cancer cell-intrinsic programmed death ligand 1 (PDL1) signals has broadened understanding of pathologic tumour PDL1 signal consequences that now includes control of tumour growth and survival pathways, stemness, immune effects, DNA damage responses and gene expression regulation as discussed by the authors .
Journal ArticleDOI

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

TL;DR: In this article , Chen et al. studied the mechanisms whereby PD-1 and/or TIGIT blockade modulate anti-tumor CD8+ T cells and found that the effectiveness of PD-L1 or anti-TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226.
Journal ArticleDOI

A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy

TL;DR: The ASPIRE nanovaccine as discussed by the authors is derived from recombinant adenovirus-infected dendritic cells in which specific peptide-major histocompatibility complex class I (pMHC-I), anti-PD1 antibody and B7 co-stimulatory molecules are simultaneously anchored by a programmed process.
References
More filters
Journal ArticleDOI

The blockade of immune checkpoints in cancer immunotherapy

TL;DR: Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Journal ArticleDOI

PD-1 and its ligands in tolerance and immunity

TL;DR: Current understanding of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential are discussed and an inhibitory bidirectional interaction between PD-L1 and B7-1 is discovered, revealing new ways the B7:CD28 family regulates T cell activation and tolerance.
Journal ArticleDOI

Oncology Meets Immunology: The Cancer-Immunity Cycle

TL;DR: Emerging clinical data suggest that cancer immunotherapy is likely to become a key part of the clinical management of cancer and may be more effective in combination with agents that target other steps of the cycle.
Related Papers (5)